MSH3-targeting exosome therapy

MSH3-targeting exosome therapy is an investigational therapeutic approach that utilizes engineered exosomes to deliver agents specifically targeting the DNA mismatch repair protein MSH3. Exosomes are small extracellular vesicles capable of transporting proteins, nucleic acids, and other molecules between cells. By loading these vesicles with therapeutic cargo—such as siRNA, miRNA, or gene-editing tools—directed against MSH3, the therapy aims to modulate or inhibit its function in target cells. This strategy leverages the natural biocompatibility and targeting capabilities of exosomes for precise drug delivery while minimizing off-target effects[1][2][4][5]. The primary indication would likely be cancers or diseases where aberrant MSH3 activity contributes to pathogenesis.